In just 1.5 years, Shine-On BioMedical (6926) has made a remarkable leap to go public—and the biotech world is taking notice! Founded with 10 years of research from Dr. Der-Yang Cho of China Medical University Hospital, Shine-On is focusing on innovative cancer treatments with two groundbreaking platforms: the HLA-G cancer target and nanobody technology.
 
Their SOA101, a triple-specific T-cell engager antibody, is poised to enter clinical trials in Taiwan, targeting solid cancers. Meanwhile, SOB102, an exosome-wrapped miRNA therapy, is in preclinical stages and aims to conquer drug-resistant brain cancer by crossing the blood-brain barrier!
 
Shine-On’s rapid rise is fueled by not only world-class technology but also the support of a strong shareholder base, including AnnJi Pharmaceutical, Ever Fortune. AI (6841), and Lumosa Therapeutics (6535), along with the backing of Taiwan’s prestigious Traditional Chinese Medicine network.
 
Keep following #Globalbio for the latest in medical breakthroughs and biotech innovations!
 
#CancerTreatment #Nanobody #ExosomeTherapy #BiotechInnovation #TripleSpecificAntibody #BloodBrainBarrier #TaiwanBiotech # ShineOn #Globalbio #FutureOfMedicine